— Know what they know.
Not Investment Advice

INTS NASDAQ

Intensity Therapeutics, Inc.
1W: -9.5% 1M: -14.0% 3M: -23.9% YTD: -66.2% 1Y: -46.6% 3Y: -96.5%
$3.44
+0.23 (+7.17%)
 
Weekly Expected Move ±7.8%
$3 $3 $3 $4 $4
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 26 · $9.3M mcap · 1M float · 2.51% daily turnover · Short 58% of daily vol

Balance Sheet Trends

Total Assets
$14M +194.8% ▲
5Y CAGR: +6.8%
Total Liabilities
$2M +19.3% ▲
5Y CAGR: -28.3%
Shareholders Equity
$12M +307.0% ▲
Cash & Investments
$12M +360.3% ▲
5Y CAGR: +5.1%
Total Debt
$110K -20.3% ▼
5Y CAGR: -26.1%
Net Debt
-$12M -381.7% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$5M$1M$9M$3M$12M
Short-Term Investments$0$0$6M$0$0
Cash & ST Investments$5M$1M$15M$3M$12M
Net Receivables$51K$62K$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$69K$14K$6K$0$0
Total Current Assets$5M$1M$15M$3M$13M
Property, Plant & Equip.$318K$139K$147K$122K$96K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$168K$167K$2M$1M$1M
Total Non-Current Assets$486K$306K$2M$1M$1M
Total Assets$5M$2M$17M$5M$14M
— Liabilities —
Accounts Payable$173K$603K$3M$1M$583K
Short-Term Debt$2M$4M$0$0$31K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$0$0$499K$56K$2M
Total Current Liabilities$4M$7M$4M$2M$2M
Long-Term Debt$0$0$0$0$79K
Other Non-Current Liab.$10M$10M$36K$0$0
Total Non-Current Liabilities$10M$10M$174K$110K$79K
Total Liabilities$14M$17M$4M$2M$2M
— Equity —
Common Stock$341$0$1K$2K$0
Retained Earnings-$31M-$39M-$51M-$67M-$78M
Accumulated OCI$0$0-$17M$0$0
Total Stockholders Equity-$9M-$15M$13M$3M$12M
Total Liabilities & Equity$5M$2M$17M$5M$14M
— Key Metrics —
Total Debt$2M$4M$158K$138K$110K
Net Debt-$2M$3M-$8M-$2M-$12M
Total Investments$0$0$6M$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms